experi
conduct
apheresi
platelet
concentr
apc
collect
cell
separ
baxter
healthcar
deerfield
il
usa
apc
contain
platelet
suspend
approxim
ml
plasma
also
known
pa
iii
pl
plastic
contain
baxter
healthcar
pct
perform
use
amotosalen
hcl
light
nm
process
devic
util
close
system
consist
seri
plastic
contain
illumin
sourc
fig
experi
use
ultraviolet
illumin
system
capabl
process
two
platelet
unit
time
model
baxter
healthcar
ultraviolet
illumin
system
deliv
j
treatment
dose
platelet
unit
min
illumin
devic
use
fluoresc
lamp
mount
illumin
tray
temperatur
control
apc
illumin
devic
agit
reciproc
shake
viral
isol
obtain
inocul
vero
cell
atcc
rockvil
md
usa
sputum
specimen
italian
patient
affect
sever
form
pneumonia
unknown
aetiolog
histori
travel
vietnam
itali
march
amplif
second
passag
viru
entir
genom
sequenc
report
genbank
access
number
vicenzi
et
al
viral
stock
obtain
vero
cell
two
addit
serial
passag
urbani
strain
specimen
number
strain
receiv
center
diseas
control
cdc
atlanta
ga
usa
viral
stock
prepar
cultur
supernat
infect
vero
cell
atcc
centrifug
remov
cell
debri
five
replic
experi
perform
strain
apc
unit
unit
ml
plasma
intersol
spike
approxim
unit
per
ml
pfu
aliquot
apc
test
min
determin
pretreat
viral
infect
titr
spike
platelet
mixtur
treat
amotosalen
j
light
briefli
use
steril
connect
devic
scd
apc
contain
spike
seri
amotosalen
contain
fig
step
apc
plasmaintersol
pass
amotosalen
contain
illumin
contain
air
express
illumin
contain
contain
platelet
concentr
amotosalen
subsequ
separ
amotosalen
contain
heat
seal
step
mixtur
place
illumin
devic
platelet
mixtur
expos
j
treatment
agit
cycl
treatment
sampl
collect
measur
viral
infect
titr
replic
experi
use
independ
unit
apc
infecti
viral
titr
measur
use
standard
plaqu
assay
vero
cell
plaqu
assay
platelet
sampl
first
dilut
tissu
cultur
medium
mix
final
concentr
incub
approxim
least
h
allow
time
clot
format
remov
centrifug
supernat
use
viral
plaqu
assay
two
five
replic
ml
approxim
apc
unit
assay
residu
infecti
viru
larger
volum
assay
increas
dynam
rang
plaqu
assay
urbani
strain
evalu
sensit
inactiv
apc
two
independ
experi
test
unit
contain
ml
apc
suspend
plasma
intersol
instead
ml
apc
unit
aliquot
spike
approxim
pfu
viru
treat
amotosalen
j
light
treatment
ml
apc
assay
residu
infect
titr
plaqu
assay
vero
cell
sampl
heparin
sulphat
u
ad
diluent
plaqu
assay
prevent
clot
sampl
test
unit
contain
serial
dilut
cell
cultur
media
either
eagl
minim
essenti
medium
earl
salt
dulbecco
modifi
eagl
medium
biowhittak
vervier
belgium
supplement
fetal
calf
serum
hyclon
perbio
scienc
erembodegem
aalst
belgium
inocul
onto
vero
cell
monolay
approxim
h
test
sampl
aspir
adher
cell
layer
overlay
media
contain
either
agaros
seaplaqu
fmc
bioproduct
rockland
usa
carboxymethylcellulos
sigma
chemic
corp
st
loui
ms
usa
day
incub
plaqu
number
score
visual
stain
necessari
neutral
red
sigma
crystal
violet
sigma
methanol
viral
rna
spike
apc
extract
use
quiagen
viral
rna
mini
kit
quiagen
inc
santa
clarita
ca
usa
accord
manufactur
instruct
quantif
viral
rna
perform
use
polymeras
chain
reaction
pcr
assay
gener
cdna
vicenzi
et
al
follow
primer
pair
probe
ttatcacccgcg
aagaagct
ctctagttgca
tgacagccctc
tgc
gtg
gat
tgg
ctt
tga
ad
univers
pcr
master
mix
appli
biosystem
foster
citi
ca
usa
nm
respect
final
volum
standard
obtain
clone
fragment
plasmid
use
ta
clone
kit
vitrogen
corp
san
diego
ca
usa
linear
distribut
r
obtain
copi
data
shown
level
viral
inactiv
calcul
use
formula
pretreat
viral
viral
titr
pct
viru
detect
viral
titr
express
infecti
unit
v
total
platelet
volum
assay
lack
viru
detect
indic
inactiv
limit
detect
thu
reduct
express
greater
input
titr
volum
platelet
concentr
assay
preliminari
experi
carri
order
measur
infect
mix
apc
absenc
amotosalen
light
treatment
purpos
urbani
viral
infect
cultur
medium
compar
viral
infect
spike
platelet
concentr
incub
platelet
mixtur
durat
experi
result
show
mean
decreas
viral
infect
titr
approxim
mix
platelet
similarli
inocul
platelet
unit
order
exceed
total
apc
volum
ml
viral
stock
ad
ml
platelet
concentr
mix
viru
apc
aliquot
remov
clot
format
retract
carri
describ
materi
method
supernat
either
test
plaqu
infect
assay
subject
rna
extract
quantif
viral
genom
incub
control
apc
ad
amotosalen
light
period
experi
result
approxim
reduct
viral
titr
pfu
viral
input
copiesml
measur
revers
chain
reaction
approxim
higher
titr
obtain
plaqu
assay
confirm
previou
observ
indic
approxim
viral
genom
requir
form
singl
plaqu
vicenzi
et
al
intercept
blood
system
inactiv
high
titr
urbani
isol
tabl
five
replic
experi
strain
pretreat
infect
titr
rang
pfuml
apc
treatment
viabl
viru
detect
test
volum
ml
demonstr
mean
rang
assay
ml
treat
platelet
sampl
increas
dynam
rang
plaqu
assay
demonstr
similarli
two
replic
experi
urbani
strain
pretreat
infect
titr
pfu
apc
treatment
viabl
viru
detect
test
volum
three
ml
demonstr
inactiv
viral
infect
respect
taken
togeth
seven
replic
mean
obtain
result
show
highli
sensit
pct
amotosalen
present
studi
demonstr
inactiv
platelet
concentr
limit
detect
mean
rang
achiev
treatment
intercept
blood
system
efficaci
pathogen
inactiv
intercept
blood
system
demonstr
two
differ
viral
isol
effect
pathogen
inactiv
system
blood
compon
must
inactiv
capabl
maintain
biolog
properti
blood
compon
develop
intercept
blood
system
platelet
describ
report
studi
perform
demonstr
inactiv
bacteria
virus
protozoa
leucocyt
platelet
concentr
lin
et
al
vanvoorhi
et
al
report
demonstr
amotosalen
plu
inactiv
novel
human
coronaviru
caus
sar
effect
inactiv
demonstr
two
independ
viral
isol
phylogenet
analysi
show
two
strain
employ
studi
common
origin
similar
origin
hong
kong
north
china
taiwan
vega
et
al
vicenzi
et
al
nucleotid
sequenc
comparison
urbani
isol
differ
six
nucleotid
chang
isol
rota
et
al
ruan
et
al
vicenzi
et
al
regard
differ
two
isol
consist
low
mutat
rate
shown
lowest
mutat
frequenc
among
rna
virus
yeh
et
al
potenti
transmiss
blood
suppli
unknown
wherea
close
contact
symptomat
patient
main
rout
transmiss
cheng
et
al
tong
liang
howev
detect
blood
infect
individu
grant
et
al
yam
et
al
current
nat
assay
howev
import
limit
detect
infect
individu
first
week
symptom
yam
et
al
drosten
et
al
ng
et
al
nat
result
occur
due
pcr
inhibitor
faulti
rna
extract
nat
result
also
report
consequ
trigger
alarm
bell
worldwid
yu
pcr
assay
modifi
order
improv
specif
sensit
lau
et
al
poon
et
al
window
period
detect
blood
remain
undefin
regard
postul
time
cours
viremia
may
rel
short
viral
load
low
detect
day
onset
symptom
chen
et
al
ng
et
al
addit
preval
individu
infect
area
remain
unknown
recent
report
support
exist
sub
clinic
nonpneumon
infect
woo
et
al
nonpneumon
infect
present
healthi
blood
donor
sar
outbreak
hong
kong
woo
et
al
although
level
viremia
report
signific
correspond
howev
gener
respond
cast
doubt
woo
find
yip
et
al
theron
young
zhou
nevertheless
pathogen
inactiv
proactiv
approach
blood
safeti
deal
new
emerg
agent
affect
safeti
blood
suppli
without
necessarili
know
level
infecti
particl
blood
stream
intercept
blood
system
util
amotosalen
light
shown
inactiv
bacteria
virus
protozoa
leucocyt
lin
et
al
vanvoorhi
et
al
lin
et
al
intercept
blood
system
nucleic
technolog
requir
specif
viral
sequenc
aggreg
data
demonstr
pct
efficaci
varieti
envelop
rna
dna
known
emerg
virus
platelet
concentr
therefor
offer
potenti
prospect
prevent
major
platelet
viral
diseas
author
thank
lorena
barzizza
suppli
apc
gianna
melucci
vigo
margaret
rheinschmit
technic
help
intercept
blood
system
kent
dupui
input
experiment
design
urbani
strain
viru
dr
thoma
ksiazek
cdc
urbani
strain
dr
lynett
sawyer
critic
read
manuscript
